Pillar 1
Intelligence
Know what's happening in FDA enforcement before it happens to you. Warning letter analysis, 483 trends, and enforcement pattern recognition — written for quality teams, not lawyers.
What happens here
FDA Warning Letter Analysis
Every significant warning letter broken down — what FDA cited, why it matters, and what it means for your quality system.
483 Trend Reports
Pattern analysis across 483 observations. See which findings are escalating and where your risk exposure sits.
Regulatory Guidance Updates
ICH, EMA, USP, and FDA guidance changes — summarized with plain-language impact assessment for your operations.
Weekly Intelligence Digests
Curated weekly roundup of the enforcement actions and guidance changes that matter most to small pharma quality teams.
Enforcement intelligence that feeds readiness work.
Warning-letter patterns, guidance changes, and quality science context stay connected to the evidence vault and readiness paths.
July 2026
Your Next 483 Observation Is Running on a Timer
Anthropic's July 2026 Managed Agents release ships scheduled autonomous runs and authenticated enterprise access. Pharma quality teams that have approved these capabilities without a QU review checkpoint built into the workflow architecture are building toward a Purolea-pattern inspection finding.
DSRV Intelligence
6 min read
July 2026
MCP Goes Stateless on July 28. For Pharma AI Teams, That Is a Change Control Event.
The MCP protocol's July 28 release candidate introduces six breaking changes and deprecates three core primitives. For pharma teams running MCP-enabled tools, the deadline is a validation checkpoint and a documentation obligation under FDA's AI-CGMP enforcement precedent.
DSRV Intelligence
5 min read
July 2026
FDA Is Treating Discarded Evidence as a Quality Unit Failure
FDA's June 22, 2026 warning letter to Genzyme Ireland shows how undocumented retesting, discarded review artifacts, and canceled deviations now read as quality-unit governance failures. Small pharma quality teams should treat this as a warning that incomplete records are no longer a narrow documentation problem.
DSRV Intelligence
7 min read
June 2026
COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.
Five CGMP warning letters in one posting cycle. Five manufacturers. The common thread: treating a supplier certificate of analysis as the endpoint of component verification instead of one data point in it. FDA's June 2026 cluster makes the distinction explicit.
DSRV Intelligence
5 min read
Found something in the intelligence that affects your site?
See how Response Strategy can help
The regulatory world doesn't slow down.
Neither should you.
Join QA professionals, regulatory affairs specialists, and stability scientists who rely on DSRV for weekly regulatory updates, quality science deep-dives, and expert commentary.
Free forever. No spam. Unsubscribe any time.
Controlled intake
Before files move, route the question safely.
DSRV starts with a controlled request: the workflow ask, context, urgency, and decision pressure. Confidential files stay out of the public homepage until the intake path confirms the right review lane.
Ask, check the vault, answer or flag the gap, then escalate to Ted/DSRV when regulated judgment matters.
Ask
What decision does the quality team need to make?
Vault
What reviewed evidence, history, or QMS context already answers it?
Gap
What is missing, ambiguous, or unsafe to answer automatically?
Ted/DSRV
What needs human review, training, response strategy, or readiness work?
Coming next: connect your AI to controlled quality intelligence. Not autonomous decisions, not uncontrolled file ingestion, and not a promise of regulatory outcome.